Renée Galá is currently Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals, plc. Previously, Ms. Galá was the Chief Financial Officer at GRAIL, Inc., a healthcare company focused on the early detection of cancer, from January 2019 to June 2019. Prior to joining GRAIL, Ms. Galá was Senior Vice President and Chief Financial Officer at Theravance Biopharma following the company’s spinout from Theravance, Inc. Ms. Galá joined Theravance (now Innoviva, Inc.) and held various roles in the finance organization before leading the company’s spin-out transaction. Before Theravance, Ms. Galá worked at Eli Lilly and Company, where she held positions of increasing responsibility in global treasury, pharmaceutical sales, and corporate strategy/business development. Prior to joining Eli Lilly, she spent seven years in the energy industry in the United States and internationally in positions focused on corporate finance, project finance, and mergers and acquisitions. Ms. Galá holds a B.S. in mathematics from Vanderbilt University and an M.B.A. from Columbia Business School.